1. At a Glance – Oncology Dreams, Africa Cash Flows & A 48.5 P/E Attitude
₹316 per share. Market cap ₹429 Cr. Stock down 21% in 3 months and 43% in 1 year. Yet trading at 48.5 times earnings. Ladies and gentlemen, welcome to the world of Medicamen Biotech Ltd — where margins are single-digit, ROE is 4.43%, but ambition is USFDA-certified.
Q3 FY26 sales came in at ₹43.49 Cr with PAT of ₹2.59 Cr. Operating margin stands at 11.68%. Debt is modest at ₹30.8 Cr with a debt-to-equity of just 0.11. Sounds stable, right? But return ratios whisper “meh” while valuation screams “premium.”
Exports contribute ~77% of revenue (FY23), with Africa forming a major chunk. Oncology facility now approved by USFDA. Preferential issue at ₹530 earlier in FY25. That’s right — someone paid ₹530, market is at ₹316.
So what’s going on here? Hidden gem? Or premium packaging over average profitability?
Let’s dissect this sterile injectable dream.
2. Introduction – Small Pharma, Big Geography, Modest Returns
Incorporated in 1993, Medicamen Biotech is not a startup kid trying to impress Shark Tank. It’s been around for over three decades.
It manufactures generic formulations and oncology products. It exports to Africa, CIS countries, Latin America and is now knocking on the US and Europe’s doors.
Sounds impressive.
But here’s the thing.
Revenue growth over 5 years? 5%.
Profit growth over 5 years? -5%.
ROE last year? 4%.
If this was a student report card, parents would say: “Beta, you’re trying… but try harder.”
The interesting twist? USFDA approval for its sterile oncology facility at Haridwar in Oct 2024. ANDA approval for Bortezomib injection in June 2025.
Now that’s serious.
So the company has moved from selling to semi-regulated African markets to stepping into regulated US & EU turf. That’s like going from district cricket to IPL trials.
But can margins keep up?
3. Business Model – WTF Do They Even Do?
Medicamen is essentially a formulation manufacturer.
They manufacture:
- Antibiotics
- Cardiovascular drugs
- Diabetes medicines
- Oncology injectables
- General pain management drugs
They operate three manufacturing
